Scarica l'app Stockscreener
0.0412
142.22%
0.0242
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GRTX Giù?
Forum
Previsione
Galera Therapeutics Inc Borsa (GRTX) Ultime notizie
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN
GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks
Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan
Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Radiation-Induced Oral Mucositis in Head and Neck Cancer Market is expected to reach USD 1.63 billion by 2034 - openPR.com
Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Galera Therapeutics holds annual stockholder meeting - Investing.com
Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H - ScienceDirect.com
Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
Mark Bachleda takes the helm at Eyconis - BioCentury
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Galera Therapeutics faces Nasdaq delisting - Investing.com
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
GRTX Stock Price and Chart — OTC:GRTX - TradingView
Galera Therapeutics Explores Strategic Options Amid Financial Results Announcement - mychesco.com
Head and Neck cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) - The Globe and Mail
Galera Adopts Limited Duration Stockholder Rights Agreement - FinancialContent
Carisma Therapeutics Appoints Eugene Kennedy as Chief Medical Officer - citybiz
Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates
0.28%
17.88%
Capitalizzazione:
|
Volume (24 ore):